Lycia Therapeutics (NASDAQ:LYCA) Stock: Insider Venrock Healthcare Capital Par Purchases 15,000 Shares

Key Points

• Venrock Healthcare Capital Par purchased 15,000 Lycia Therapeutics shares at an average price of $25.45, increasing its position by 0.22% to 6,840,233 shares valued at approximately $174.1 million.
• The major shareholder made several additional purchases from October 23–30, including 1.95 million shares acquired on October 26 for approximately $35.2 million.
• Lycia shares fell $1.33 to $26.40 in Friday trading. The biotechnology company is developing LYTAC medicines designed to eliminate disease-causing extracellular and cell-surface proteins.

Lycia Therapeutics, Inc. (NASDAQ:LYCA - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 15,000 shares of the company's stock in a transaction that occurred on Wednesday, October 28th. The shares were purchased at an average price of $25.45 per share, with a total value of $381,750.00. Following the completion of the transaction, the insider directly owned 6,840,233 shares of the company's stock, valued at $174,083,929.85. This represents a 0.22% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par acquired 9,004 shares of Lycia Therapeutics stock. The stock was purchased at an average price of $26.28 per share, for a total transaction of $236,625.12.
• On Thursday, October 29th, Venrock Healthcare Capital Par acquired 1,000 shares of Lycia Therapeutics stock. The stock was purchased at an average price of $26.33 per share, for a total transaction of $26,330.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par bought 39,796 shares of Lycia Therapeutics stock. The shares were acquired at an average cost of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par bought 1,952,705 shares of Lycia Therapeutics stock. The shares were acquired at an average cost of $18.04 per share, with a total value of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $25.91 per share, with a total value of $1,371,649.49.

Lycia Therapeutics Price Performance

Shares of NASDAQ:LYCA traded down $1.33 during midday trading on Friday, hitting $26.40. The company's stock had a trading volume of 202,428 shares, compared to its average volume of 857,210. Lycia Therapeutics, Inc. has a 12-month low of $22.19 and a 12-month high of $36.49.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company's approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia's technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.